Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma.
In present investigation, we developed a novel hyaluronated cationic nanostructured lipid carrier (CNLCs) which contains CPT-11/irinotecan to target CD44 biomarker which commonly overexpresses on colon cancer. The cationic core NLCs was developed by using capmule MCM and compritol as mix lipid phase with 150 ± 2.5 nm particles size and 93.98 ± 2.5% entrapment efficiency. The cationic core NLCs were coated with hyaluronic acid by ionic conjugation. The particle size of hyaluronated CNLCs was enhanced to 255 ± 4.2 nm. In-vitro drug release studies revealed a slow and sustain release of the drug and a practically no leaching of coumarin-6. The confocal laser microscopy studies were performed with developed CNLCs in two CD44 overexpressing cell lines (HT-29 and Colo-320). The studies revealed marked uptake of the CNLCs by both the cell lines in just two hours. The results were comparable to the FITC conjugated CD44 antibodies. Therefore, the developed dual purpose CNLCs were found to be highly specific for CD44 biomarker. The developed formulations were found to be compatible with blood components. The MTT assay revealed that the developed particles had enhanced cytotoxicity against non-MDR as well MDR cancer cells.
['Negi|Lalit Mohan|LM|', 'Jaggi|Manu|M|', 'Joshi|Vidushi|V|', 'Ronodip|Kar|K|', 'Talegaonkar|Sushama|S|']
D000230:Adenocarcinoma D002166:Camptothecin D003110:Colonic Neoplasms D003374:Coumarins D016503:Drug Delivery Systems D018432:Drug Resistance, Multiple D019008:Drug Resistance, Neoplasm D015972:Gene Expression Regulation, Neoplastic D019073:HT29 Cells D006801:Humans D018960:Hyaluronan Receptors D006820:Hyaluronic Acid D000077146:Irinotecan D008055:Lipids D053758:Nanoparticles D013844:Thiazoles
Hyaluronic acid MDR CD44